OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
November 06, 2023
Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, talks about the differences in designing E&L testing for combination products vs. conventional pharmaceuticals.
November 03, 2023
Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, recommends some key issues that pharma manufacturers should consider when formulating products that require a medical device.
November 29, 2022
The decision to move forward in Phase III development stems from the threat of resistance to current malaria treatment growth.
September 02, 2022
While a variety of innovations have already impacted the drug delivery landscape, improving sustainability and having the ability to make smaller volumes of drug products still require work.
December 13, 2021
A look at how linker technology for antibody drug conjugates has evolved.
October 12, 2021
AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.
November 10, 2017
The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization approval for AstraZeneca’s benralizumab, a monoclonal antibody for treating severe asthma.
September 28, 2017
Nemera is now authorized to handle, assemble, sterilize, and store pharmaceutical drugs and medicinal products for autoinjector combination products at its facility in Neuenburg, Germany.
April 01, 2017
OrlaSURF technology can be used for the development of target-binding assays to monitor the binding of an ADC to its antigen.
March 01, 2017
Communication and taking the time to develop the process are key to successful transfer and scale up of biologics